10-K · February 24, 2026
FibroBiologics is a clinical-stage biotech developing fibroblast-based therapies (CYWC628, CYMS101, CybroCellTM) and is advancing a Phase 1/2 wound-healing study planned to start in Q1 2026 and an IND for MS planned in…
Earnings analysis · 10-Q
FBLG earnings analysis
Filed April 30, 2026 · Our reading of the company's report
The latest report
FibroBiologics reported a net loss of $5.0 million for Q1 2026, comparable to a loss of $4.966 million in the prior year. Operating expenses increased to $5.068 million driven primarily by higher R&D costs due to…
Read full summary
FibroBiologics reported a net loss of $5.0 million for Q1 2026, comparable to a loss of $4.966 million in the prior year. Operating expenses increased to $5.068 million driven primarily by higher R&D costs due to clinical trial preparations. The company's cash and equivalents decreased to $1.5 million with an accumulated deficit of $59.2 million, indicating ongoing financial challenges.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-5
What stood out
-
Steady Net Loss
Net loss for Q1 2026 was $5.0 million, virtually unchanged from $4.966 million in Q1 2025.
-
Increased R&D Spend
R&D expenses rose to $2.953 million in Q1 2026, up from $1.780 million a year prior, an increase of $1.173 million.
-
Cash Position Decline
Cash and cash equivalents decreased to $1.5 million as of March 31, 2026, down from higher levels in prior periods.
-
Operational Efficiency Efforts
Management is focusing on reducing operating expenses while maintaining R&D activities.
-
Recurring Operating Losses
The accumulated deficit reached $59.2 million as of March 31, 2026, indicating sustained financial losses.
-
Compliance with Nasdaq
Successfully maintained compliance with Nasdaq's equity rule and bid price rule, ensuring continued listing.
What to watch
-
Going Concern Warning
There is substantial doubt regarding the company's ability to continue as a going concern due to ongoing operating losses and net cash used.
-
R&D Investment Risks
Increased expenses in R&D are necessary but pose risks of generating potential losses without guaranteed returns.
-
Manufacturing Challenges
Issues related to manufacturing processes could delay product availability and strain financial resources.
Management's outlook
Management expects continued operating losses and is focused on raising capital to fund ongoing operations and R&D.
Earlier filings 4
10-Q · October 31, 2025
FibroBiologics reported a Q3 net loss of $5,778 (net loss per share $0.13) and a nine‑month net loss of $15,402, continuing to generate no revenue. Cash and cash equivalents declined to $4,867 (from $13,985 at December…
10-Q · July 31, 2025
FibroBiologics reported a Q2 2025 net loss of $4.658M (EPS -$0.12) vs net income $0.898M (EPS $0.03) in Q2 2024, driven by higher operating expenses — R&D $2.041M (Q2 2025) up from $0.975M. Cash declined to $8.845M at…
10-K · March 31, 2025
FibroBiologics is a clinical-stage cell therapy company focused on fibroblast-based therapies (lead candidates: CYWC628, CYMS101, CybroCellTM) and plans a twelve-week Phase 1/2 diabetic foot ulcer trial in Australia in…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.